These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 17966289)

  • 21. Multiple sclerosis: interferon beta for some serious forms.
    Prescrire Int; 2007 Dec; 16(92):252-7. PubMed ID: 18092425
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predicting and preventing the future: actively managing multiple sclerosis.
    Hutchinson M
    Pract Neurol; 2009 Jun; 9(3):133-43, discussion 144. PubMed ID: 19448055
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genome-wide pharmacogenomic analysis of the response to interferon beta therapy in multiple sclerosis.
    Byun E; Caillier SJ; Montalban X; Villoslada P; Fernández O; Brassat D; Comabella M; Wang J; Barcellos LF; Baranzini SE; Oksenberg JR
    Arch Neurol; 2008 Mar; 65(3):337-44. PubMed ID: 18195134
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Why did IL-12/IL-23 antibody therapy fail in multiple sclerosis?
    Longbrake EE; Racke MK
    Expert Rev Neurother; 2009 Mar; 9(3):319-21. PubMed ID: 19271940
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Non-conventional medicine and multiple sclerosis].
    Vermersch P; Zéphir H
    Rev Neurol (Paris); 2008 Mar; 164 Spec No 1():F7-13. PubMed ID: 18680811
    [No Abstract]   [Full Text] [Related]  

  • 26. Brain atrophy assessment in multiple sclerosis: importance and limitations.
    Giorgio A; Battaglini M; Smith SM; De Stefano N
    Neuroimaging Clin N Am; 2008 Nov; 18(4):675-86, xi. PubMed ID: 19068408
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Central nervous system effects of current and emerging multiple sclerosis-directed immuno-therapies.
    Antel JP; Miron VE
    Clin Neurol Neurosurg; 2008 Nov; 110(9):951-7. PubMed ID: 18502570
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The use of visual art for stress relief: a case report of newly diagnosed multiple sclerosis.
    Kelly NA
    Explore (NY); 2009; 5(3):167-70. PubMed ID: 19409363
    [No Abstract]   [Full Text] [Related]  

  • 29. [Immunoablation and autologous hematopoietic stem cell transplantation (AHSCT) in multiple sclerosis].
    Créange A; Farge-Bancel D
    Rev Neurol (Paris); 2008 Mar; 164(3):207-15. PubMed ID: 18405770
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The therapy of multiple sclerosis with immune-modulating or immunosuppressive drug. A critical evaluation based upon evidence based parameters and published systematic reviews.
    Clerico M; Rivoiro C; Contessa G; Viglietti D; Durelli L
    Clin Neurol Neurosurg; 2008 Nov; 110(9):878-85. PubMed ID: 18164542
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Stem cells in therapy of multiple sclerosis].
    Narkilahti S; Hovatta O; Elovaara I
    Duodecim; 2009; 125(9):965-73. PubMed ID: 19517865
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vibration therapy in multiple sclerosis: a pilot study exploring its effects on tone, muscle force, sensation and functional performance.
    Schyns F; Paul L; Finlay K; Ferguson C; Noble E
    Clin Rehabil; 2009 Sep; 23(9):771-81. PubMed ID: 19561035
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Concepts of induction and escalation therapy in multiple sclerosis.
    Rieckmann P
    J Neurol Sci; 2009 Feb; 277 Suppl 1():S42-5. PubMed ID: 19200866
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Psychological aspects of multiple sclerosis.
    José Sá M
    Clin Neurol Neurosurg; 2008 Nov; 110(9):868-77. PubMed ID: 18022759
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Editorial: multiple sclerosis].
    Vermersch P
    Rev Neurol (Paris); 2009 Mar; 165 Suppl 4():S111. PubMed ID: 19361674
    [No Abstract]   [Full Text] [Related]  

  • 36. Symptomatic therapies in multiple sclerosis. Introduction.
    Solaro C; Mancardi G
    Neurol Sci; 2008 Dec; 29 Suppl 4():S347. PubMed ID: 19089673
    [No Abstract]   [Full Text] [Related]  

  • 37. [Complementary and alternative therapies for multiple sclerosis].
    Schwarz S; Leweling H; Sagstetter BU; Meinck HM
    Med Monatsschr Pharm; 2008 Mar; 31(3):89-98; quiz 99-100. PubMed ID: 18429530
    [No Abstract]   [Full Text] [Related]  

  • 38. [Therapy monitoring in patients with multiple sclerosis based on transcriptomic analysis].
    Zettl UK; Goertsches RH
    Fortschr Neurol Psychiatr; 2009 Aug; 77 Suppl 1():S64-8. PubMed ID: 19685398
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of interferon-beta therapy on innate and adaptive immune responses to the human endogenous retroviruses HERV-H and HERV-W, cytokine production, and the lectin complement activation pathway in multiple sclerosis.
    Petersen T; Møller-Larsen A; Thiel S; Brudek T; Hansen TK; Christensen T
    J Neuroimmunol; 2009 Oct; 215(1-2):108-16. PubMed ID: 19766328
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Could cytokines levels or adhesion molecules expression be predictor of IFN-beta treatment response in multiple sclerosis patients?
    Sega S; Horvat A; Rot U; Wraber B; Ihan A
    Clin Neurol Neurosurg; 2008 Nov; 110(9):947-50. PubMed ID: 18396372
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.